Aadi Bioscience, (id:5487 AADI)
2.30 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:23:22 AM)
Exchange closed, opens in 1 day 23 hours
0.00 USD (0.00%)
6.24 USD (6.24%)
6.98 USD (6.98%)
22.99 USD (22.99%)
-51.06 USD (-51.06%)
-70.79 USD (-70.79%)
-96.70 USD (-96.70%)
About Aadi Bioscience,
Market Capitalization 56.69M
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
| Headquarters (address) |
17383 Sunset Boulevard Pacific Palisades 90272 CA United States |
| Phone | 424 744 8055 |
| Website | https://aadibio.com |
| Employees | 70 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | AADI |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.21 - 5.70 |
| Market Capitalization | 56.69M |
| P/E trailing | -0.943 |
| P/E forward | -2.28 |
| Price/Sale | 2.26 |
| Price/Book | 0.822 |
| Beta | 0.369 |
| EPS | -2.28 |
| EPS United States (ID:6, base:3400) | 24.26 |